Ratings Aurora Cannabis Inc.

Equities

ACB

CA05156X8504

Delayed Toronto S.E. Other stock markets 14:58:08 01/05/2024 BST			5-day change	1st Jan Change
10.42 ^CAD	-17.63%		+6.54%	+60.46%

04-30	Health Care Flat Amid Mixed Earnings -- Health Care Roundup	DJ
04-30	TSX Down More Than 1% Today and More Than 2% For April, Having Hit Record Highs Earlier In the Month; But Cannabis Stocks Hit a High	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past four months, analysts' average price target has been revised downwards significantly.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AURORA CANNABIS INC.	+60.46%	502M		D+
DONG-E-E-JIAO CO.,LTD.	+39.33%	6.11B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.38%	4.35B		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.17%	3.18B		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.98%	3.16B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.41%	2.51B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+48.74%	1.98B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-4.82%	1.74B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.24%	1.63B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-8.96%	1.6B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes